Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction

Bibliography

• Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog 2013;60:25-31. quiz 32
   PubMedGoogle Scholar
• Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002;71:9-15
   PubMed Web of Science ®Google Scholar
• Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25:1232-8
   PubMed Web of Science ®Google Scholar
• Vaidya JS, Baldassarre G, Thorat MA, Massarut S. Role of glucocorticoids in breast cancer. Curr Pharm Des 2010;16:3593-600
   PubMed Web of Science ®Google Scholar
• Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9:571-91
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:239-48
   PubMed Web of Science ®Google Scholar
• Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169-75
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003;56:327-30
   PubMed Web of Science ®Google Scholar
• Hromadkova L, Soukup T, Vlcek J. Important drug interactions in patients with rheumatic disorders: interactions of glucocorticoids, immunosuppressants and antimalarial drugs. Drugs Today (Barc) 2012;48:545-53
   PubMed Web of Science ®Google Scholar
• Dvorak Z, Pavek P. Regulation of drug-metabolizing cytochrome p450 enzymes by glucocorticoids. Drug Metab Rev 2010;42:621-35
   PubMed Web of Science ®Google Scholar
• David nelson's p450 homepage. Available from: http://drnelson.Utmem.Edu/human.P450.Table.Html
   Google Scholar
• Anzenbacher P, Anzenbacherova E. Cytochromes p450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47
   PubMed Web of Science ®Google Scholar
• Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab 2008;19:331-9
   PubMed Web of Science ®Google Scholar
• Revollo JR, Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 2009;1179:167-78
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Kaestner KH, Wessely O, et al. Analysis of glucocorticoid signalling by gene targeting. J Steroid Biochem Mol Biol 1998;65:111-15
   PubMed Web of Science ®Google Scholar
• Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA. Structural determinants of DNA-binding specificity by steroid receptors. Mol Endocrinol 1995;9:389-400
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001;79:376-84
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Schuetz EG, Thottassery JV, et al. Identification of a novel dexamethasone responsive enhancer in the human cyp3a5 gene and its activation in human and rat liver cells. Mol Pharmacol 1996;49:63-72
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of cyp2c9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002;277:209-17
   PubMed Web of Science ®Google Scholar
• Pavek P, Cerveny L, Svecova L, et al. Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of p-glycoprotein, cyp3a4, and cyp2c9 genes in placental trophoblast cell lines. Placenta 2007;28:1004-11
   PubMed Web of Science ®Google Scholar
• Chen Y, Goldstein JA. The transcriptional regulation of the human cyp2c genes. Curr Drug Metab 2009;10:567-78
   PubMed Web of Science ®Google Scholar
• Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the cyp2c19 promoter. Mol Pharmacol 2003;64:316-24
   PubMed Web of Science ®Google Scholar
• Ferguson SS, Chen Y, LeCluyse EL, et al. Human cyp2c8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane x receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005;68:747-57
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane x receptor (hpxr) and correlation to known cyp3a4 drug interactions. Curr Drug Metab 2006;7:375-88
   PubMed Web of Science ®Google Scholar
• Onica T, Nichols K, Larin M, et al. Dexamethasone-mediated up-regulation of human cyp2a6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4{alpha} to the proximal promoter. Mol Pharmacol 2008;73:451-60
   PubMed Web of Science ®Google Scholar
• Barwick JL, Quattrochi LC, Mills AS, et al. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human cyp3a4 and rabbit cyp3a6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 1996;50:10-16
   PubMed Web of Science ®Google Scholar
• Ogg MS, Williams JM, Tarbit M, et al. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human cyp3a4 gene in vitro. Xenobiotica 1999;29:269-79
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation of the cyp3a4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane x receptors. Drug Metab Dispos 2000;28:493-6
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of cyp3a4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane x receptor response element. Drug Metab Dispos 2002;30:1029-34
   PubMed Web of Science ®Google Scholar
• Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome p450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008;9:129-43
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of cyp2b6, cyp2c9 and cyp3a4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-53
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of cyp3a4 in hepatocytes. Curr Drug Metab 2007;8:185-94
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane x receptor and retinoid x receptor-alpha expression in human hepatocytes: synergistic increase of cyp3a4 induction by pregnane x receptor activators. Mol Pharmacol 2000;58:361-72
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Gerbal-Chaloin S, et al. Dual effect of dexamethasone on cyp3a4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane x receptor. Eur J Biochem 2001;268:6346-58
   PubMedGoogle Scholar
• Pascussi JM, Gerbal-Chaloin S, Fabre JM, et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome p450 gene regulation. Mol Pharmacol 2000;58:1441-50
   PubMed Web of Science ®Google Scholar
• Harper PA, Riddick DS, Okey AB. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol 2006;72:267-79
   PubMed Web of Science ®Google Scholar
• Linder MW, Falkner KC, Srinivasan G, et al. Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Drug Metab Rev 1999;31:247-71
   PubMed Web of Science ®Google Scholar
• Monostory K, Pascussi JM, Kobori L, Dvorak Z. Hormonal regulation of cyp1a expression. Drug Metab Rev 2009;41:547-72
   PubMed Web of Science ®Google Scholar
• Vrzal R, Stejskalova L, Monostory K, et al. Dexamethasone controls aryl hydrocarbon receptor (ahr)-mediated cyp1a1 and cyp1a2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact 2009;179:288-96
   PubMed Web of Science ®Google Scholar
• Kosir R, Spaninger K, Rozman D. Circadian events in human diseases and in cytochrome p450-related drug metabolism and therapy. IUBMB Life 2013;65:487-96
   PubMed Web of Science ®Google Scholar
• Lu YF, Jin T, Xu Y, et al. Sex differences in the circadian variation of cytochrome p450 genes and corresponding nuclear receptors in mouse liver. Chronobiol Int 2013;30:1135-43
   PubMed Web of Science ®Google Scholar
• Li AP, Maurel P, Gomez-Lechon MJ, et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome p450 induction. Chem Biol Interact 1997;107:5-16
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 2008;4:837-54
   PubMed Web of Science ®Google Scholar
• Wadhwa NK, Schroeder TJ, Pesce AJ, et al. Cyclosporine drug interactions: a review. Ther Drug Monit 1987;9:399-406
   PubMed Web of Science ®Google Scholar
• Backman L, Kreis H, Morales JM, et al. Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol 2002;54:65-8
   PubMed Web of Science ®Google Scholar
• Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to cyp3a5 and mdr1 polymorphisms and steroids. Transplantation 2005;80:977-84
   PubMed Web of Science ®Google Scholar
• van Duijnhoven EM, Boots JM, Christiaans MH, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003;16:721-5
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003;18:2409-14
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004;43:741-62
   PubMed Web of Science ®Google Scholar
• Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 2008;42:1037-47
   PubMed Web of Science ®Google Scholar
• Teo YL, Saetaew M, Chanthawong S, et al. Effect of cyp3a4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012;133:703-11
   PubMed Web of Science ®Google Scholar
• Ranson M, Reck M, Anthoney A, et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (nsclc): a phase I dose-finding study. Ann Oncol 2010;21:2233-9
   PubMed Web of Science ®Google Scholar
• Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004;103:67-72
   PubMed Web of Science ®Google Scholar
• Urien S, Doz F, Giraud C, et al. Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Cancer Chemother Pharmacol 2011;67:597-603
   PubMed Web of Science ®Google Scholar
• Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome p450 3a4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-hodgkin's lymphoma. Clin Pharmacokinet 2011;50:781-91
   PubMed Web of Science ®Google Scholar
• Bruggemann SK, Pfaffle S, Peters SO, Wagner T. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab Dispos 2007;35:1721-4
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hardy RW, Thiessen JJ, et al. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988;44:622-8
   PubMed Web of Science ®Google Scholar
• Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12
   PubMed Web of Science ®Google Scholar
• Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987;37:1561-2
   PubMed Web of Science ®Google Scholar
• Song IH, Borland J, Chen S, et al. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013;57:4394-7
   PubMed Web of Science ®Google Scholar
• Nakajima M, Suzuki T, Sasaki T, et al. Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. Ther Drug Monit 1999;21:507-13
   PubMed Web of Science ®Google Scholar
• Villikka K, Varis T, Backman JT, et al. Effect of methylprednisolone on cyp3a4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 2001;57:457-60
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Potentiation of vitamin k antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 2000;132:631-5
   PubMed Web of Science ®Google Scholar
• Sellam J, Costedoat-Chalumeau N, Amoura Z, et al. Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and al amyloidosis. Joint Bone Spine 2007;74:446-52
   PubMed Web of Science ®Google Scholar
• Henricsson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990;66:49-52
   PubMedGoogle Scholar
• Lin JH. Cyp induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23:1089-116
   PubMed Web of Science ®Google Scholar
• Blumberg B, Sabbagh W Jr, Juguilon H, et al. Sxr, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12:3195-205
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
   PubMed Web of Science ®Google Scholar
• Needs CJ, Smith M, Boutagy J, et al. Comparison of methylprednisolone (1 g i.V.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. J Rheumatol 1988;15:224-8
   PubMed Web of Science ®Google Scholar
• Narang PK, Wilder R, Chatterji DC, et al. Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following ‘high-dose' pulse administration. Biopharm Drug Dispos 1983;4:233-48
   PubMed Web of Science ®Google Scholar
• Novotna A, Pavek P, Dvorak Z. Construction and characterization of a reporter gene cell line for assessment of human glucocorticoid receptor activation. Eur J Pharm Sci 2012;47:842-7
   PubMed Web of Science ®Google Scholar
• DRUGDEX® System [Internet database]. Greenwood Village CTHUp
   Google Scholar